Astrazeneca (AZN) said Tuesday that baxdrostat has been accepted for priority review by the US Food and Drug Administration to treat adults with hard-to-control hypertension.
The submission was based on results from a phase 3 trial, which showed that the drug met the primary and all secondary endpoints, the company said.
The drugmaker said it expects a Prescription Drug User Fee Act action date during Q2 2026.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.